Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9799254 | 0.86 | POLB (0.38) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL103249 | 0.86 | POLB (0.38) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL395350 | 0.82 | HTT (0.41) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL1568243 | 0.82 | ALDH1A1 (0.37) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL2963613 | 0.82 | DHFR (0.38) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL12797845 | 0.81 | HTT (0.42) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL27593883 | 0.81 | HTT (0.42) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL15272 | 0.79 | ALDH1A1 (0.42) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL394710 | 0.78 | NOS3 (0.39) | POLBHTTDHFRNOS3NOS1 | |
| SCHEMBL6549465 | 0.77 | ALDH1A1 (0.37) | POLBHTTDHFRNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153978-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20050048115-A1 | Buprenorphine microspheres | INSYS THERAPEUTICS, INC. | 2005-03-03 | — | — | US | disclosed |
| EP-1487441-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080125-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153978-A1 | Medicaments | GRK1, ROCK1, GRK7 | POLB 4482/4885HTT 4712/4885DHFR 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.